A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

A groundbreaking study has uncovered the origin of one of the most aggressive forms of ovarian cancer, called high-grade ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer. Now, researchers ...

The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ...

Researchers say fast-track testing can identify aggressive cancer making diagnosis quicker and giving a better chance of ...

They found serous tubal intraepithelial carcinoma (STIC), a precancerous lesion, in uterine serous carcinoma and serous ovarian carcinoma but not in nonserous uterine cancer or benign conditions.

Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovarian tumor, making it challenging to characterize adequately. As a result, current treatment approaches are often ...